Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen

BACKGROUND: Neoadjuvant cisplatin-based chemotherapy is standard care prior to radical cystectomy in patients with muscle-invasive bladder cancer (MIBC). OBJECTIVE: To assess efficacy and safety of two commonly used neoadjuvant schedules with different total doses and dose-intensities of gemcitabine...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Karin Holmsten, Lise Høj Omland, Anne Birgitte Als, Mads Agerbæk, Line Hammer Dohn, Henriette Lindberg, Niels Viggo Jensen, Andreas Carus, Mette Moe, Abolfazl Hosseini, Cecilia Radkiewicz, Helle Pappot, Anders Ullén
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	SAGE Publishing 2022-03-01
Rangatū:	Bladder Cancer
Urunga tuihono:	https://doi.org/10.3233/BLC-211556
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!